A Single Arm, Multi-center Study to Assess the Long-term Real-world Safety and Effectiveness of Nucala in EGPA Patients Who Have Already Used Nucala for at Least 96 Weeks in Japan
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Mepolizumab (Primary)
- Indications Churg-Strauss syndrome
- Focus Adverse reactions
- Acronyms MARS
- Sponsors GlaxoSmithKline; GSK
- 15 Jun 2024 Results assessing the Long-Term (=96 Weeks) Safety and Effectiveness of Mepolizumab , presented at the 25th Annual Congress of the European League Against Rheumatism
- 23 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2021 Planned End Date changed from 3 Mar 2023 to 3 Apr 2023.